Vass C, Menapace R, Strenn K, Rainer G
Department of Ophthalmology, University of Vienna, Austria.
Ophthalmic Surg Lasers. 1998 Sep;29(9):714-21.
To determine whether intrascleral exposure to mitomycin-C (MMC) improves the control of intraocular pressure (IOP), increases the incidence of complications, or both.
The authors retrospectively evaluated 38 eyes of 29 patients following the intraoperative application of MMC (0.2 mg/ml; 5 minutes). In 21 eyes the MMC-soaked sponge was applied to the intact episclera (episcleral group). In 17 eyes, two sponges, one episcleral and the other intrascleral (sandwich group), were applied. The median follow-up times were 19.0 (episcleral group) and 24.0 (sandwich group) months. Outcome measures were the IOP, the number of medications, success rates, and the incidence of complications.
The only statistically significant difference between the two groups was the 2-week postoperative IOP, which was significantly lower in the episcleral group (P = .0314).
Because there is no additional benefit, the authors recommend that the intrascleral application of MMC be avoided. However, they did not observe increased complication rates when MMC was applied in this way.
确定巩膜内暴露于丝裂霉素-C(MMC)是否能改善眼压(IOP)控制、增加并发症发生率或两者兼有。
作者回顾性评估了29例患者的38只眼,这些眼在术中应用了MMC(0.2mg/ml;5分钟)。21只眼将MMC浸泡的海绵应用于完整的巩膜上(巩膜组)。17只眼应用了两块海绵,一块在巩膜上,另一块在巩膜内(三明治组)。中位随访时间分别为19.0(巩膜组)和24.0(三明治组)个月。观察指标为眼压、用药数量、成功率及并发症发生率。
两组间唯一具有统计学意义的差异是术后2周的眼压,巩膜组显著更低(P = 0.0314)。
由于没有额外益处,作者建议避免巩膜内应用MMC。然而,他们并未观察到以这种方式应用MMC时并发症发生率增加。